Literature DB >> 16091248

The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.

Grace A Lee1, Madhu N Rao, Carl Grunfeld.   

Abstract

Since the introduction of HIV protease inhibitors (PIs), disorders of glucose and lipid metabolism have emerged. In dissecting out the direct effect on lipid and glucose metabolism, it has become apparent that individual PIs have different effects on metabolism. Some PIs such as indinavir acutely induce insulin resistance. PIs have also been shown to cause other disorders of glucose metabolism, including impairment of insulin secretion and increased endogenous glucose production. Individual PIs also have different effects on lipid metabolism. Ritonavir predominantly increases triglyceride and very low-density lipoprotein cholesterol levels. Limited studies in HIV-negative volunteers suggest that several of the PIs do not increase low-density lipoprotein cholesterol levels. This review examines the direct effects of PIs on glucose and lipid metabolism by assessing prospective studies of HIV-infected and healthy normal volunteers, and in vitro studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091248     DOI: 10.1007/s11904-996-0008-z

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  74 in total

1.  Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.

Authors:  Esteban Martínez; Pere Domingo; María J Galindo; Ana Milinkovic; Juan A Arroyo; Francisco Baldovi; María Larrousse; Agathe León; Elisa de Lazzari; José M Gatell
Journal:  Clin Infect Dis       Date:  2004-03-15       Impact factor: 9.079

2.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

Authors:  K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan
Journal:  J Acquir Immune Defic Syndr       Date:  2000-01-01       Impact factor: 3.731

3.  Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices.

Authors:  Qiang Tong; Jean-Louis Sankalé; Colleen M Hadigan; Guo Tan; Eric S Rosenberg; Phyllis J Kanki; Steven K Grinspoon; Gökhan S Hotamisligil
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

4.  Indinavir induces acute and reversible peripheral insulin resistance in rats.

Authors:  Paul W Hruz; Haruhiko Murata; Haijun Qiu; Mike Mueckler
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

Review 5.  Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

Authors:  Morris Schambelan; Constance A Benson; Andrew Carr; Judith S Currier; Michael P Dubé; John G Gerber; Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Kathleen Mulligan; William G Powderly; Michael S Saag
Journal:  J Acquir Immune Defic Syndr       Date:  2002-11-01       Impact factor: 3.731

6.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

Authors:  G Behrens; A Dejam; H Schmidt; H J Balks; G Brabant; T Körner; M Stoll; R E Schmidt
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

7.  Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

Authors:  Robert L Murphy; Ian Sanne; Pedro Cahn; Praphan Phanuphak; Lisa Percival; Thomas Kelleher; Michael Giordano
Journal:  AIDS       Date:  2003-12-05       Impact factor: 4.177

8.  Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.

Authors:  Michael P Dubé; Dajun Qian; Hannah Edmondson-Melançon; Fred R Sattler; Diane Goodwin; Carmen Martinez; Vanessa Williams; Debra Johnson; Thomas A Buchanan
Journal:  Clin Infect Dis       Date:  2002-07-23       Impact factor: 9.079

9.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; M Pang; W Doerrler; J K Shigenaga; P Jensen; K R Feingold
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

10.  A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.

Authors:  Cesar Fisac; Nuria Virgili; Elena Ferrer; Maria J Barbera; Emilio Fumero; Concepcio Vilarasau; Daniel Podzamczer
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

View more
  11 in total

Review 1.  The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.

Authors:  Mustafa A Noor
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

Review 2.  Non-communicable Diseases in Pregnant and Postpartum Women Living with HIV: Implications for Health Throughout the Life Course.

Authors:  Risa M Hoffman; Caitlin Newhouse; Brian Chu; Jeffrey S A Stringer; Judith S Currier
Journal:  Curr HIV/AIDS Rep       Date:  2021-01-05       Impact factor: 5.071

3.  Effects of combined alcohol and anti-HIV drugs on cellular stress responses in primary hepatocytes and hepatic stellate and kupffer cells.

Authors:  Jay Hu; Hui Han; Mo Yin Lau; Harrison Lee; Michelle MacVeigh-Aloni; Cheng Ji
Journal:  Alcohol Clin Exp Res       Date:  2015-01       Impact factor: 3.455

Review 4.  The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.

Authors:  Oliver P Flint; Mustafa A Noor; Paul W Hruz; Phil B Hylemon; Kevin Yarasheski; Donald P Kotler; Rex A Parker; Aouatef Bellamine
Journal:  Toxicol Pathol       Date:  2009-01-26       Impact factor: 1.902

Review 5.  HIV therapy, metabolic syndrome, and cardiovascular risk.

Authors:  Vivian Pao; Grace A Lee; Carl Grunfeld
Journal:  Curr Atheroscler Rep       Date:  2008-02       Impact factor: 5.113

6.  Understanding the complications of antiretroviral drugs.

Authors:  Carl Grunfeld
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

7.  Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients.

Authors:  Ninon Taylor; Iris Kremser; Simon Auer; Gregor Hoermann; Richard Greil; Elisabeth Haschke-Becher; Harald Esterbauer; Lukas Kenner; Hannes Oberkofler
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731

8.  Relationship between leptin levels and suppressed CD4 counts in HIV patients.

Authors:  Mariam Al-Fadhli; Mohammad Saraya; Jafar Qasem; Fawaz Azizieh; Shahab Shahab; Raj Raghupathy
Journal:  Med Princ Pract       Date:  2012-06-21       Impact factor: 1.927

9.  Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs.

Authors:  Esther Muya; Appolinary Kamuhabwa
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec

10.  The Effect of Antiretroviral Therapy on SIRT1, SIRT3 and SIRT6 Expression in HIV-Infected Patients.

Authors:  Karolina Jurkowska; Beata Szymańska; Brygida Knysz; Agnieszka Piwowar
Journal:  Molecules       Date:  2022-02-17       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.